Headache and Migraine

A driver sees what appear to be squiggly lines in the right field of vision of her right eye.

The pediatric critical care medicine attending physician in the Department of Anesthesiology and Critical Care Medicine at the Children’s Hospital of Philadelphia spoke about how physicians can better address brain death in pediatric patients.

If approved, eptinezumab, an Alder Biopharmaceuticals product, would become the fourth member of the CGRP class, and the only member available for quarterly infusions.

The framework consists of 2 documents that expand on the agency’s plans for its risk-based approach for describing drugs, devices, and biologics, including those designated as regenerative medicine advanced therapies.

As many patients with migraine and other disorders are resistant to currently available options, this increase in device development has brought forward additional path­ways to treatment for patients.

In this podcast, Dr Heidi Moawad interviews a neurologist currently researching new, available treatments in headache medicine.

Find concise summaries of the latest management recommendations and research findings in this brief highlights slideshow.

The phase 2 trial for the CGRP receptor agonist is planned for Q2 of 2019 after the intranasal treatment met its target therapeutic exposures in phase 1. Biohaven submitted an IND to the FDA in September 2018.

The Director of the Jefferson Headache Center spoke about migraine therapies that hold excitement and promise in the new year.

The acute administration of adhesive dermally applied microarray zolmitriptan (Qytripta, Zosano Pharma) showed an almost uniform benefit across subgroups of patients with severe pain, delayed treatment, nausea, and who were awakening with headache.

The mist-like nasal spray acts rapidly and is well tolerated and is formulated using Intravail to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action.

The director of the MedStar Georgetown University Hospital Headache Center discussed the importance of understanding the biologic mechanisms of migraine for patients and providers.

A recent review of the ICER report on calcitonin gene-related peptide inhibitor monoclonal antibodies has suggested that due to their cost and comparative benefit to available treatments, they should be reserved as second-line treatments.

Neurology News Network for the week of January 19, 2019.

The American Headache Society President spoke with NeurologyLive about the recent AHS position statement on the use of migraine treatments in clinical practice

The guidance provided the society’s recommendations for the use of the newly approved calcitonin gene-related peptide monoclonal antibodies for the prevention of migraine, among other guidance points.

The AAN position statement author further addressed the opposing position of the Nevada law, the AAN’s position on brain death, and what clinicians need to know in regard to determining it.

The Chair of the AAN’s Ethics, Law and Humanities Committee spoke to the American Academy of Neurology’s goal to improve the consistency of determining brain death.

Migraine sufferers who are trying to cut back on alcoholic beverages in 2019 may find additional motivation for their New Year’s resolution.

A review of existing guidelines and principles for treating migraine released by the American Headache Society.

Results from the largest global survey of its kind reveals that migraine sufferers who have not responded to preventive treatment experience a substantial burden of disease.

This guide includes everything you need to know about erenumab-aooe (Aimovig, Amgen/Novartis) for the preventive treatment of migraine in adults.

The Clinical Director of the NHGRI spoke about the impact of the NIH program and its future development.

Neurology News Network for the week of January 5, 2019.

The position statement’s author noted that a lack of specificity in laws and inconsistencies in protocols has led to confusion surrounding brain death in several high-profile cases.

The program’s director spoke about its genesis and evolution into a more widespread initiative which has helped improve next-generation genome sequencing.

Some migraine sufferers who do not initially respond to galcanezumab may show clinically meaningful improvement if they stay on the drug for longer periods of time.

Neurology News Network for the week of December 22, 2018.

Patients treated with fremanezumab experienced highly significant reduction in the monthly average number of migraine days for both monthly and quarterly dosing regimens.

This brief year-end slideshow highlights significant progress in research into migraine, Alzheimer disease, stroke, multiple sclerosis, and autism.